106.50
price down icon0.19%   -0.345
 
loading
Schlusskurs vom Vortag:
$106.85
Offen:
$106.56
24-Stunden-Volumen:
326.01K
Relative Volume:
0.22
Marktkapitalisierung:
$212.82B
Einnahmen:
$51.72B
Nettoeinkommen (Verlust:
$11.94B
KGV:
18.11
EPS:
5.88
Netto-Cashflow:
$13.81B
1W Leistung:
-2.88%
1M Leistung:
+7.64%
6M Leistung:
-4.28%
1J Leistung:
+6.09%
1-Tages-Spanne:
Value
$106.45
$106.70
1-Wochen-Bereich:
Value
$106.00
$108.73
52-Wochen-Spanne:
Value
$92.35
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
75,883
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2025-01-31
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Vergleichen Sie NVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
106.45 212.82B 51.72B 11.94B 13.81B 5.88
Drug Manufacturers - General icon
LLY
Lilly Eli Co
868.00 822.10B 45.04B 10.59B -2.28B 11.71
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
80.90 371.73B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
JNJ
Johnson Johnson
154.92 344.63B 88.82B 14.07B 19.03B 5.79
Drug Manufacturers - General icon
ABBV
Abbvie Inc
191.04 338.99B 56.33B 4.28B 15.62B 2.40
Drug Manufacturers - General icon
MRK
Merck Co Inc
85.88 251.88B 64.17B 17.12B 14.84B 6.7297

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-04 Hochstufung Deutsche Bank Hold → Buy
2024-12-04 Herabstufung HSBC Securities Hold → Reduce
2024-09-11 Herabstufung BofA Securities Buy → Neutral
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Feb 11, 2025

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal - Benzinga

Feb 11, 2025
pulisher
Feb 11, 2025

Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK

Feb 11, 2025
pulisher
Feb 07, 2025

ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Feb 07, 2025
pulisher
Feb 06, 2025

Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News

Feb 06, 2025
pulisher
Feb 06, 2025

Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online

Feb 06, 2025
pulisher
Feb 03, 2025

HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise

Feb 03, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q2 2023 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis at ASH - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q1 2023 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 31, 2025

J.P. Morgan Healthcare Conference 2024 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis Financial Results – Q2 2024 - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Building belonging - Novartis

Jan 31, 2025
pulisher
Jan 31, 2025

Novartis in Society Integrated Report 2024 - Novartis

Jan 31, 2025
pulisher
Jan 28, 2025

Novartis to Report Q4 Earnings: What's in the Offing? - Yahoo Finance

Jan 28, 2025
pulisher
Jan 28, 2025

AI Pharma: 2 Paths to AI-Powered Drug Investment - sharewise

Jan 28, 2025
pulisher
Jan 24, 2025

Inari Medical Inc (NASDAQ: NARI): Getting A Free Pass? - Stocks Register

Jan 24, 2025
pulisher
Jan 24, 2025

Metrics That Matter About Deutsche Bank AG (NYSE: DB) - Stocks Register

Jan 24, 2025
pulisher
Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Jan 10, 2025

Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 10, 2025
pulisher
Jan 09, 2025

South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Japan Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 09, 2025

Canada Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025
pulisher
Jan 06, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 06, 2025
pulisher
Dec 23, 2024

RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead

Dec 23, 2024
pulisher
Dec 19, 2024

Communiqué de presse - GlobeNewswire Inc.

Dec 19, 2024
pulisher
Dec 17, 2024

Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance

Dec 17, 2024
pulisher
Dec 13, 2024

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart

Dec 13, 2024
pulisher
Dec 13, 2024

Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha

Dec 13, 2024
pulisher
Dec 09, 2024

Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.

Dec 09, 2024
pulisher
Dec 05, 2024

5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News

Dec 05, 2024
pulisher
Dec 04, 2024

Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart

Dec 04, 2024
pulisher
Dec 04, 2024

5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar

Dec 04, 2024

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general MRK
$85.95
price down icon 0.31%
$293.71
price down icon 0.23%
drug_manufacturers_general PFE
$25.40
price down icon 1.58%
drug_manufacturers_general SNY
$53.83
price up icon 1.03%
$102.26
price up icon 6.80%
Kapitalisierung:     |  Volumen (24h):